Pharmaceutical Business review

Ariad secures $22.8 million in financing

Investors also received 0.75 of a warrant, exercisable at a price of $2.15 per share, for each share of common stock. The warrants have a three-year term from the date of issuance and are exercisable beginning six months after the date of issuance.

The transaction is expected to close on or about February 25, 2009, subject to satisfaction of customary closing conditions. Lazard Capital Markets served as the sole placement agent for the offering.